Design of combretastatin A-4 analogs as tubulin targeted vascular disrupting agent with special emphasis on their cis-restricted isomers

Current Pharmaceutical Design

Volumn 19, Issue 10, 2013, Pages 1923-1955

  Rajak, Harish ^a   Dewangan, Pramod Kumar ^a   Patel, Vijay ^a   Jain, Deepak Kumar ^a   Singh, Avineesh ^a   Veerasamy, Ravichandran ^b   Sharma, Prabodh Chander ^c   Dixit, Anshuman ^d  

^a GURU GHASIDAS UNIVERSITY   (India)

^b AIMST UNIVERSITY   (Malaysia)

^c KURUKSHETRA UNIVERSITY   (India)

^d INSTITUTE OF LIFE SCIENCES   (India)

Author keywords

Anticancer; Antimitotic agents; Antitubulin; Antivascular; CA 4; Combretum caffrum; Cytotoxicity; Structure activity relationship

Indexed keywords

AZETIDINONE DERIVATIVE; BENZOFURAN DERIVATIVE; BENZOTHIOPHENE DERIVATIVE; COLCHICINE; COMBRETASTATIN A4; COUMARIN DERIVATIVE; FURAN DERIVATIVE; IMIDAZOLE DERIVATIVE; INDOLE DERIVATIVE; ISOXAZOLE DERIVATIVE; OXADIAZOLE DERIVATIVE; OXAZOLE DERIVATIVE; PYRAZOLE DERIVATIVE; PYRROLE DERIVATIVE; QUINAZOLINE DERIVATIVE; QUINOLINE DERIVATIVE; TETRAZOLE DERIVATIVE; THIAZOLE DERIVATIVE; THIOPHENE DERIVATIVE; TRIAZOLE DERIVATIVE; TUBULIN; VASCULAR TARGETING AGENT;

ANTINEOPLASTIC ACTIVITY; CANCER CELL CULTURE; CELL DEATH; DRUG BINDING; DRUG CYTOTOXICITY; DRUG DESIGN; DRUG EFFECT; DRUG SYNTHESIS; DRUG TARGETING; GENE THERAPY; HUMAN; IC 50; ISOMER; ISOMERIZATION; MEDICINAL CHEMISTRY; MICROTUBULE; MITOSIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; STRUCTURE ACTIVITY RELATION; TUMOR VASCULARIZATION;

ANIMALS; BLOOD VESSELS; HUMANS; ISOMERISM; STILBENES; STRUCTURE-ACTIVITY RELATIONSHIP; TUBULIN;

EID: 84876727508     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612811319100013     Document Type: Review

References (162)

1. Dowing KH, Nogales E. Tubulin and microtubule structure. Curr Opin Cell Biol 1998; 10: 16-22.
2. Nguyen TL, McGrath C, Hermone AR, et al. A common pharmacophore for a diverse set of colchicine site inhibitors using a structure-based approach. J Med Chem 2005; 48: 6107-16.
3. Pettit GR, Cragg GM, Herald DL, Schmidt JM, Lobavanijaya P. Can J Chem 1982; 60: 1374-6.
4. Hamel E, Lin CM. Interactions of combretastatin, a new plantderived antimitotic agent with tubulin. Biochem Pharmacol 1983; 32: 3864-7.
5. Lin CM, Singh SB, Chu PS, Dempcy RO, Schmidt JM, Pettit GR. Interactions of tubulin with potent natural and synthetic analogs of the antimitotic agent combretastatin: a structure-activity study. Mol Pharmacol 1988; 34: 200-8.
6. Lin CM, Ho HH, Pettit GR, Hamel E. Antimitotic natural products Combretastatin A-4 and combretastatin A-2: studies on the mechanism of their inhibition of the binding of colchicine to tubulin. Biochemistry 1989; 28: 6984-91.
7. Pettit GR, Singh SB, Hamel E, Lin CM, Alberts DS, Garcia-Kendall D. Isolation and structure of the strong cell growth and tubulin inhibitor Combretastatin A-4. Experientia 1989; 45: 209-11.
8. Woods JA, Hadfield JA, Pettit GR, Fox BW, McGown AT. The interaction with tubulin of a series of stilbenes based on Combretastatin A-4. Br J Cancer 1995; 71: 705-11.
9. Bedford SB, Quarterman CP, Rathbone DL, Slack JA, Griffin RJ, Stevens MFG. Synthesis of water-soluble prodrugs of the cytotoxic agent combretastatin A-4. Bioorg Med Chem Lett 1996; 6: 157-60.
10. Brown RT, Fox BW, Hadfield JA, McGown AT, Mayalarp SP, Pettit GR. Synthesis of water-soluble sugar derivatives of Combretastatin A-4. J Chem Soc Perkin Trans 1995; 1: 577-81.
11. Hadimani MB, Hua J, Jonklaas MD, Kessler RJ, Sheng Y, Olivares A. Synthesis, in vitro, and in vivo evaluation of phosphate ester derivatives of combretastatin A-4. Bioorg Med Chem Lett 2003; 13: 1505-8.
12. Pettit GR, Temple C Jr, Narayanan VL, Varma R, Simpson MJ, Boyd MR. Antineoplastic agents 322. Synthesis of combretastatin A-4 prodrug. Anticancer Drug Des 1995; 10: 299-309.
13. Pettit GR, Rhodes MR. Antineoplastic agents 389. New syntheses of the combretastatin A-4 prodrug. Anticancer Drug Des 1998; 13: 183-91.
14. Tron GC, Pagliai F, Del Grosso ED, Genazzani AA, Sorba G. Synthesis and cytotoxic evaluation of combretafurazans. J Med Chem 2005; 48: 3260--8.
15. Wang L, Woods KW, Li Q, et al. Potent orally active heterocyclebased combretastatin A-4 analogs: synthesis structure-activity relationship, pharmacokinetics and in vivo antitumor activity evaluation. J Med Chem 2002; 45: 1697-711.
16. Sun CM, Lin LG, Yu HJ, et al. Synthesis and cytotoxic activities of 4,5-diarylisoxazoles. Bioorg Med Chem Lett 2007; 17: 1078-81.
17. Flynn BL, Hamel E, Jung MK. A one-pot synthesis of Benzo[b]furan and indole inhibitors of tubulin polymerization. J Med Chem 2002; 45: 2670-73.
18. Little M, Seehaus T. Comparative Analysis of Tubulin Sequence. Comparative Biochemistry and Physiology. Comp Biochem Physiol. 1988, 90B: 655-70.
19. Nogales E, Wolf SG, Downing KH. Structure of the β, α tubulin dimer by electron crystallography. Nature 1998; 391: 199-203.
20. Downing KH, Nogalest E. Tubulin structure: insights into microtubule properties and functions. Curr Opin Struct Biol 1998; 8: 785-91.
21. Ludueiia RF, Banerjee A, Khan IA. Tubulin structure and biochemistry. Curr Opin Cell Biol 1992; 4: 53-7.
22. Caplow M. Microtubule dynamics. Curr Opin Cell Biol 1992, 4: 58-65
23. Desbene S, Renault SG. Drugs that Inhibit Tubulin Polymerization: The Particular Case of Podophyllotoxin and Analogs. Curr Med Chem-Anti-Cancer Agents, 2002; 2: 71-90.
24. Pinney KG, Mejia MP, Villalobos VM, et al. Synthesis and biological evaluation of aryl azide derivatives of combretastatin A-4 as molecular probes for tubulin. Bioorg Med Chem 2000; 8: 2417-25.
25. Lopez-Fanarraga M, Avila J, Guasch A, Coll M, Zabala JC. Review: postchaperonin tubulin folding cofactors and their role in microtubule dynamics. J Struct Biol 2001; 135: 219-29.
26. Nogales E, Wang HW. Structural mechanisms underlying nucleotide dependent self-assembly of tubulin and its relatives. Curr Opin Struct Biol 2006; 16: 221-229.
27. Mandelkow E, Mandelkow EM. Microtubular structure and tubulin polymerization. Curr Opin Cell Biol 1989; 1: 5-9.
28. Risinger AL, Giles FJ, Mooberry SL. Microtubule dynamics as a target in oncology. Cancer Treat Rev 2009; 35: 255-61
29. Beckman RA, Weiner LM, Davis HM. Protein engineering strategies to improve exposure in solid tumors. Cancer 2006; 109: 170-9
30. Hasani A, Leighl N. Classification and Toxicities of Vascular Disrupting Agents. Clinical Lung Cancer 2011; 12: 18-25
31. Griggs J, Metcalfe JC, Hesketh R. Targeting tumour vasculature: the development of combretastatin A4. Lancet Oncol 2001; 2: 82-7.
32. Tozer GM, Prise VE, Wilson J, et al. Combretastatin A-4 Phosphate as a Tumor Vascular-Targeting Agent: Early Effects in Tumors and Normal Tissues. Cancer Res 1999; 59: 1626-34.
33. Gridelli C, Rossi A, Maione P, et al. Vascular Disrupting Agents: A Novel Mechanism of Action in the Battle against Non-Small Cell Lung Cancer. The Oncologist 2009; 14: 612-20.
34. Lippert JW, Vascular disrupting agents. Bioorg Med Chem 2007; 15: 605-15.
35. Lin CM, Singh SB, Chu PS, et al Interactions of tubulin with potent natural and synthetic analogs of the antimitotic agent combretastatin: a structure-activity study. Mol Pharmacol 1988; 34: 200-8.
36. Woods JA, Hadfield JA, Pettit GR, Fox BW, McGown AT. The interaction with tubulin of a series of stilbenes based on Combretastatin A-4. Br J Cancer 1995; 71: 705-11.
37. Tozer GM, Kanthou C, Baguley BC. Disrupting tumor blood vessels. Nat Rev Cancer 2005; 5: 423-35.
38. Kanthou C, Tozer GM. The tumor vascular targeting agent combretastatin A-4 phosphate induces reorganization of the actin cytoskeleton and early membrane blebbing in human endothelial cells. Blood 2002; 99: 2060-9.
39. Tozer GM, Kanthou C, Parkins CS, Hill SA. The biology of the combretastatins as tumour vascular targeting agent. Int J Exp Pathol 2002; 83: 21-38.
40. Thorpe PE, Chaplin DJ, Backley DC. The first international conference on vascular targeting: Meeting overview. Cancer Res 2003; 63: 1144-7.
41. Liekens S, Clercq ED, Neyts J. Angiogenesis: regulators and clinical applications. Biochem Pharmacol 2001; 61: 253-70.
42. Tozer GM, Prise VE, Wilson J, et al. Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate: intravital microscopy and measurement of vascular permeability. Cancer Res 2001; 61: 6413-22.
43. Vincent L, Kermani P, Young LM, et al. Combretastatin A-4 phosphate induces rapid regression of tumor neovessels and growth through interference with vascular endothelial-E-cadherin signaling. J Clin Invest 2005; 15: 2992-3006.
44. Bacher G, Emig T, Emig P, Klenner T, Kutscher B, Nickel B. New small-molecule tubulin inhibitors. Pure Appl Chem 2001; 73: 1459-64.
45. Bhattacharyya B, Panda D, Gupta S, Banerjee M. Anti-mitotic activity of colchicine and the structural basis for its interaction with tubulin. Med Res Rev 2008; 28: 155-83.
46. Jordan A, Hadfield JA, Lawrence NJ, McGown AT. Tubulin as a target for anticancer drugs: Agents which interact with the mitotic spindle. Med Res Rev 1998; 18: 259-96.
47. Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer 2004; 4: 253-65.
48. Tozer GM, Kanthou C, Baguley BC. Disrupting tumour blood vessels. Nat Rev Cancer 2005; 5: 423-35.
49. Griggs J, Metcalfe JC, Hesketh R. Targeting tumour vasculature: the development of combretastatin A-4. The Lancet Oncol 2001; 2: 82-7.
50. Kerr DJ, Hamel E, Jung MK, Flynn BL. The concise synthesis of chalcone, indanone and indenone analogs of combretastatin A4. Bioorg Med Chem 2007; 15: 3290-8.
51. Nam NH. Combretastatin A-4 analogs as antimitotic antitumor agents. Curr Med Chem 2003; 10: 1697-722.
52. Li Q, Sham HL. Discovery and development of antimitotic agents that inhibit tubulin polymerisation for the treatment of cancer. Expert Opin Ther Patents 2002; 12: 1663-702.
53. Bibby MC. Combretastatin anticancer drugs. Drug Future 2002; 27: 475-80.
54. Adams J, Elliott PJ. New agents in cancer clinical trials. Oncogene 2000; 19: 6687-92.
55. Liekens S, De Clercq E, Neyts J. Angiogenesis: regulators and clinical applications. Biochem Pharmacol 2001; 61: 253-70.
56. Verdier-Pinard P, Lansiaux A, Bailly C. Combretastatin A-4 phosphate. Bull Cancer 2001; 88: 235-9.
57. Randal J. Antiangiogenesis drugs target specific cancers, mechanisms. J Natl Cancer Inst 2000; 92: 520-2.
58. Puduvalli VK, Sawaya R. Antiangiogenesis-therapeutic strategies and clinical implications for brain tumors. J Neurooncol 2000; 50: 189-200.
59. Hsieh HP, Liou JP, Mahindroo N. Pharmaceutical design of antimitotic agents based on combretastatins. Curr Pharm Design 2005; 11: 1655-77.
60. Lawrence NJ, McGown AT. The chemistry and biology of antimitotic chalcones and related enone systems. Curr Pharm Design 2005; 11: 1679-93.
61. Chaudhary A, Pandeya SN, Kumar P, et al Combretastatin A-4 analogs as anticancer agents. Mini Rev Med Chem 2007; 7: 1186-205
62. Shan Y, Zhang J, Liu Z, Wang M, Dong Y. Developments of combretastatin A-4 derivatives as anticancer agents. Curr Med Chem 2011; 18: 523-38.
63. Marrelli M, Conforti F, Statti GA, et al. Biological potential and structure-activity relationships of most recently developed vascular disrupting agents: an overview of new derivatives of natural combretastatin A-4. Curr Med Chem 2011; 18: 3035-81.
64. Sun L, Vasilevich NI, Fuselier JA, Hocart SJ, Coy DH. Examination of the 1,4-disubstituted azetidinone ring system as a template for combretastatin A-4 conformationally restricted analog design. Bioorg Med Chem Lett 2004; 14: 2041-6.
65. Yang Z. Synthesis and In-vitro biological activity evaluation of the derivatives of combretastatin A-4. Lett Drug Des Discov 2006; 3: 544-6.
66. Carr M, Greene LM, Knox AJS, Lloyd DG, Zisterer DM, Meegan MJ. Lead identification of conformationally restricted β-lactam type combretastatin analogs: Synthesis antiproliferative activity and tubulin targeting effects. Eur J Med Chem 2010; 45: 5752-66.
67. Singh P, Raj R, Kumar V, et al. 1 2 3-Triazole tethered β-lactam-Chalcone bifunctional hybrids: Synthesis and anticancer evaluation. Eur J Med Chem 2011; 46: 1-7.
68. O'Boyle NM, Carr M, Greene LM, et al. Synthesis and evaluation of azetidinone analogs of combretastatin A-4 as tubulin targeting agents. J Med Chem 2010; 53: 8569-84.
69. O'Boyle NM, Carr M, Greene LM, et al. Synthesis evaluation and structural studies of antiproliferative tubulin-targeting azetidin-2-ones. Bioorg Med Chem 2011; 19: 2306-25.
70. O'Boyle NM, Carr M, et al. Synthesis biochemical and molecular modelling studies of antiproliferative azetidinones causing microtubule disruption and mitotic catastrophe. Eur J Med Chem 2011; 46: 4595-607.
71. Banwell MG, Hamel E, Hockless DCR, Verdier-Pinard P, Willisa AC, Wong DJ. 4 5-Diaryl 1H-pyrrole-2-carboxylates as Combretastatin A-4/lamellarin T hybrids: Synthesis and evaluation as antimitotic and cytotoxic agents. Bioorg Med Chem 2006; 14: 4627-38.
72. Kim Y, Nam NH, You YJ, Ahn BZ. Synthesis and cytotoxicity of 3 4-Diaryl 2(5H)-furanones. Bioorg Med Chem Lett 2002; 12: 719-22.
73. Pirali T, Busacca S, Beltrami L, et al. Synthesis and cytotoxic evaluation of combretafurans potential scaffolds for dual-action antitumoral agents. J Med Chem 2006; 49: 5372-6.
74. Theeramunkong S, Caldarelli A, Massarotti A, et al. Regioselective Suzuki coupling of dihaloheteroaromatic compounds as a rapid strategy to synthesize potent rigid combretastatin analogs. J Med Chem 2011; 54: 4977-86.
75. Flynn BL, Flynn GP, Hamel E, Jung MK. The synthesis and tubulin binding activity of thiophene-based analogs of combretastatin A-4. Bioorg Med Chem Lett 2001; 11: 2341-3.
76. Romagnoli R, Baraldi PG, Pavani MG, et al. Synthesis and biological evaluation of 2-amino-3-(3'4'5'-trimethoxybenzoyl)-5-aryl thiophene as a new class of potent antitubulin agents. J Med Chem 2006; 49: 3906-15.
77. Romagnoli R, Baraldi PG, Remusat V, et al. Synthesis and biological evaluation of 2-(3'4'5'-trimethoxybenzoyl)-3-amino-5-aryl thiophenes as a new class of tubulin inhibitors. J Med Chem 2006; 49: 6425-8.
78. Romagnoli R, Baraldi PG, Maria DC, et al. Design synthesis and biological evaluation of thiophene analogs of chalcones. Bioorg Med Chem 2008; 16: 5367-76.
79. Romagnoli R, Baraldi PG, Lopez OC, et al. Synthesis of novel antimitotic agents based on 2-amino-3-aroyl-5-(hetero)-arylethynyl thiophene derivatives. Bioorg Med Chem Lett 2011; 21: 2746-51.
80. Ohsumi K, Hatanaka T, Fujita K, et al. Synthesis and antitumor activity cis restricted combretastatins: 5-membered heterocyclic analog. Bioorg Med Chem Lett 1998; 8: 3153-8.
81. Gududuru V, Hurh E, Dalton JT, Miller DD. Discovery of 2-Arylthiazolidine-4 carboxylic acid amides as a new class of cytotoxic agents for prostate cancer. J Med Chem 2005; 48: 2584-8.
82. Gududuru V, Hurh E, Sullivan J, Dalton JT, Miller DD. SAR studies of 2-arylthiazolidine-4-carboxylic acid amides: A novel class of cytotoxic agents for prostate cancer. Bioorg Med Chem Lett 2005; 15: 4010-3.
83. Li W, Lu Y, Wang Z, Dalton JT, Miller DD. Synthesis and antiproliferative activity of thiazolidine analogs for melanoma. Bioorg Med Chem Lett 2007; 17: 4113-7.
84. Lu Y, Li CM, Wang Z, Ross CR, Chen J, Dalton JT. Li W Miller DD. Discovery of 4-substituted methoxybenzoyl-aryl-thiazoles as novel anticancer agents: synthesis biological evaluation and structure activity relationships. J Med Chem 2009; 52: 1701-11.
85. Lu Y, Wang Z, Li CM, et al. Synthesis in vitro structure activity relationship and in vivo studies of 2-arylthiazolidine-4-carboxylic acid amides as anticancer agents. Bioorg Med Chem 2010; 18: 477-95.
86. Lu Y, Li CM, Wang Z, et al. Design Synthesis and SAR Studies of 4-Substituted methoxybenzoyl-aryl-thiazoles analogs as potent and orally bioavailable anticancer agents. J Med Chem 2011; 54: 4678-93.
87. Li CM, Wang Z, Lu Y, et al. Biological activity of 4-substituted methoxybenzoyl-aryl-thiazole: an active microtubule inhibitor. Cancer Res 2011; 71: 216-24.
88. Romagnoli R, Baraldi PG, Lopez-Cara C, et al. Balzarini J Brancale A Fu XH Li J Zhang SZ Hamel E. One-pot synthesis and biological evaluation of 2-pyrrolidinyl-4-amino-5-(3'4'5'-trimethoxybenzoyl) thiazole: A unique highly active antimicrotubule agent. Eur J Med Chem 2011; 46: 6015-24.
89. Bhat BA, Dhar KL, Puri SC, Saxena AK, Shanmugavel M, Qazi GN. Synthesis and biological evaluation of chalcones and their derived pyrazoles as potential cytotoxic agents. Bioorg Med Chem Lett 2005; 15: 3177-80.
90. LeBlanc R, Dickson J, Brown T, et al. Synthesis and cytotoxicity of epoxide and pyrazole analogs of the combretastatins. Bioorg Med Chem 2005; 13: 6025-34.
91. Burja B, Cimbora-Zovko T, Tomic S, Jelusic T, Kocevar M, Polanc S, Osmak M. Pyrazolone-fused combretastatins and their precursors: synthesis cytotoxicity antitubulin activity and molecular modeling studies. Bioorg Med Chem 2010; 18: 2375-87.
92. Congiu C, Onnis V, Vesci L, Castorina M, Pisano C. Synthesis and in vitro antitumor activity of new 4 5-dihydropyrazole derivatives. Bioorg Med Chem 2010; 18: 6238-48.
93. Liu T, Cui R, Chen J, Zhang J, He Q, Yang B, Hu Y. 4,5-Diaryl-3-aminopyrazole derivatives as analogs of combretastatin A-4: Synthesis and biological evaluation. Arch Pharm Chem Life Sci 2011; 11: 279-86.
94. Lee M, Brockway O, Dandavati A, et al. A novel class of transmethylpyrazoline analogs of combretastatins: Synthesis and invitro biological testing. Eur J Med Chem 2011; 46: 3099-104.
95. Nam NH, Kim Y, You YJ, Hong DH, Ki HM, Ahn BZ. Combretoxazolones: Synthesis, cytotoxicity and antitumor activity. Bioorg Med Chem Lett 2001; 11: 3073-6.
96. Simoni D, Grisolia G, Giannini G, et al. Heterocyclic and phenyl double-bond-locked combretastatin analogs possessing potent apoptosis-inducing activity in HL60 and in MDR cell lines. J Med Chem 2005; 48: 723-36.
97. Maya ABS, Perez-Melero C, Salvador N, Pelaez R, Caballero E, Medarde M. New naphthyl combretastatins: modifications on the ethylene bridge. Bioorg Med Chem 2005; 13: 2097-107.
98. Kaffy J, Pontikis R, Carrez D, Croisy A, Monneret C, Florent JC. Isoxazole-type derivatives related to combretastatin A-4 synthesis and biological evaluation. Bioorg Med Chem 2006; 14: 4067-77.
99. Liu T, Dong X, Xue N, Wub R, He Q, Yang B, Hua Y. Synthesis and biological evaluation of 34-diaryl-5-aminoisoxazole derivatives. Bioorg Med Chem 2009; 17: 6279-85.
100. Kamal A, Reddy JS, Ramaiah MJ, et al. Design synthesis and biological evaluation of 3,5-diaryl-isoxazoline/isoxazole pyrrolobenzodiazepine conjugates as potential anticancer agents. Eur J Med Chem 2010; 45: 3924-37.
101. Kamal A, Bharathi EV, Reddy JS, et al. Synthesis and biological evaluation of 3,5-diaryl isoxazoline/isoxazole linked 2,3 dihydroquinazolinone hybrids as anticancer agents. Eur J Med Chem 2011; 46: 691-703.
102. Bellina F, Cauteruccio S, Montib S, Rossia R. Novel imidazolebased combretastatin A-4 analogs: evaluation of their in vitro antitumor activity and molecular modeling study of their binding to the colchicine site of tubulin. Bioorg Med Chem Lett 2006; 16: 5757-62.
103. Bonezzi K, Taraboletti G, Borsotti P, Bellina F, Rossi R, Giavazz R. Vascular disrupting activity of tubulin-binding 15-diaryl-1Himidazoles. J Med Chem 2009; 52: 7906-10.
104. Congiu C, Cocco MT, Onnis V. Design synthesis and in vitro antitumor activity of new 1,4-diarylimidazole-2-ones and their 2-thione analogs. Bioorg. Med. Chem. Lett. 2008; 18: 989-93.
105. Xue N, Yang X, Wu R, et al. Synthesis and biological evaluation of imidazol-2-one derivatives as potential antitumor agents. Bioorg Med Chem 2008; 16: 2550-7.
106. Chen J, Wang Z, Lu Y, Dalton JT, Miller DD, Li W. Synthesis and antiproliferative activity of imidazole and imidazoline analogs for melanoma. Bioorg Med Chem Lett 2008; 18; 3183-7.
107. Chen J, Wang Z, Li CM, et al. Discovery of novel 2-aryl-4-benzoyl-imidazoles targeting the colchicines binding site in tubulin as potential anticancer agents. J Med Chem 2010; 53: 7414-27.
108. Schobert R, Biersack B, Dietrich A, Effenberger K, Knauer S, Mueller T. 4-(3-Halo/amino-45-dimethoxyphenyl)-5-aryloxazoles and-N-methylimidazoles that are cytotoxic against Combretastatin A-4 resistant tumor cells and vascular disrupting in a cisplatin resistant germ cell tumor model. J Med Chem 2010; 53: 6595-602.
109. Li YW, Liu J, Liu N, et al. Imidazolone-amide bridges and their effects on tubulin polymerization in cis-locked vinylogous combretastatin A-4 analogs: Synthesis and biological evaluation. Bioorg Med Chem 2011; 19: 3579-84.
110. Kiselyov AS, Semenova MN, Chernyshova NB, et al. Novel derivatives of 1,3,4-oxadiazoles are potent mitostatic agents featuring strong microtubule depolymerizing activity in the sea urchin embryo and cell culture assays. Eur J Med Chem 2010; 45: 1683-97.
111. Kumar D, Patel G, Chavers AK, Chang KH, Shah K. Synthesis of novel 1,2,4-oxadiazoles and analogs as potential anticancer agents. Eur J Med Chem 2011; 46: 3085-92.
112. Hu Y, Lu X, Luo Y, Yan R, Li QS, Zhu HL. Design, synthesis, biological evaluation and molecular modeling of 1,3,4-oxadiazoline analogs of combretastatin A-4 as novel antitubulin agents. Bioorg Med Chem 2012; 20: 903-9.
113. Lee L, Robb LM, Lee M, et al. Design, synthesis and biological evaluations of 2,5-diaryl,2,3-dihydro-1,3,4-oxadiazoline analogs of combretastatin A-4. J Med Chem 2010; 53: 325-34.
114. Ouyang X, Chen X, Piatnitski EL, et al. Synthesis and structureactivity relationships of 1,2,4-triazoles as a novel class of potent tubulin polymerization inhibitors. Bioorg Med Chem Lett 2005; 15: 5154-9.
115. Zhang Q, Peng Y, Wang XI, Keenan SM, Arora S, Welsh WJ. Highly potent triazole-based tubulin polymerization inhibitors. J Med Chem 2007; 50: 749-54.
116. Odlo K, Fournier-Dit-Chabert J, Ducki S, Gani OABSM, Sylte I, Skrede M, Hansen TV. 1 2 3-Triazole analogs of combretastatin A-4 as potential microtubule-binding agents. Bioorg Med Chem 2010; 18: 6874-85.
117. Odlo K, Hntzen J, Fournier-Dit-Chabert J, et al. 1,5-Disubstituted 1,2,3-triazoles as cis-restricted analogs of combretastatin A-4: synthesis molecular modeling and evaluation as cytotoxic agents and inhibitors of tubulin. Bioorg Med Chem 2008; 16: 4829-38.
118. Romagnoli R, Baraldi PG, Cruz-Lopez O, et al. Synthesis and antitumor activity of 1,5-disubstituted 1,2,4-triazoles as cisrestricted combretastatin analogs. J Med Chem 2010; 53: 4248-58.
119. Romagnoli R, Baraldi PG, Salvador MK, et al. Synthesis and evaluation of 1,5-Disubstituted tetrazoles as rigid analogs of combretastatin A-4 with potent antiproliferative and antitumor activity. J Med Chem 2012; 55: 475-88.
120. Medarde M, Ramos AC, Caballero E, et al. Synthesis and pharmacological activity of diarylindole derivatives. Cytotoxic agents based on combretastatins. Bioorg Med Chem Lett 1999; 9: 2303-8.
121. Mahboobi S, Pongratz H, Hufsky H, Hockemeyer J, Frieser M, Lyssenko A. Synthetic 2-aroylindole derivatives as a new class of potent tubulin-inhibitory antimitotic agents. J Med Chem 2001; 44: 4535-53.
122. Liou JP, Chang YL, Kuo FM, et al. Concise synthesis and structure-activity relationships of combretastatin A-4 analogs 1-Aroylindoles and 3-Aroylindoles as novel classes of potent antitubulin agents. J Med Chem 2004; 47: 4247-57.
123. Liou JP, Mahindroo N, Chang CW, et al. Structure-activity relationship studies of 3-Aroylindoles as potent antimitotic agents. Chem Med Chem 2006; 1: 1106-18.
124. Liou JP, Wu CY, Hsieh HP, et al. 4-and 5-Aroylindoles as novel classes of potent antitubulin agents. J Med Chem 2007; 50: 4548-52.
125. Lai MJ, Kuo CC, Yeh TK, et al. Synthesis and structure-activity relationships of 1-Benzyl-4,5,6-trimethoxyindoles as a novel class of potent antimitotic agents. Chem Med Chem 2009; 4: 588-93.
126. Martino GD, Regina GL, Coluccia A, et al. Arylthioindoles potent inhibitors of tubulin polymerization. J Med Chem 2004; 47: 6120-3.
127. Martino GD, Edler MC, Regina GL, et al. Arylthioindoles potent inhibitors of tubulin polymerization. 2. structure activity relationships and molecular modeling studies. J Med Chem 2006; 49: 947-54.
128. Regina GL, Edler MC, Brancale A, et al. Arylthioindole inhibitors of tubulin polymerization. 3. Biological evaluation structureactivity relationships and molecular modeling studies. J Med Chem 2007; 50: 2865-74.
129. Regina GL, Sarkar T, Bai R, et al. New arylthioindoles and related bioisosteres at the sulfur bridging group. 4. Synthesis tubulin polymerization cell growth inhibition and molecular modeling studies. J Med Chem 2009; 52: 7512-7.
130. Regina GL, Bai R, Rensen W, et al. Design and synthesis of 2-Heterocyclyl-3-arylthio-1H-indoles as potent tubulin polymerization and cell growth inhibitors with improved metabolic stability J Med Chem 2011; 54: 8394-406.
131. Pandit B, Sun Y, Chen P, et al. Structure-activity-relationship studies of conformationally restricted analogs of combretastatin A-4 derived from SU5416 Bioorg Med Chem 2006; 14: 6492-501.
132. Dupeyre G, Chabot GG, Thoret S, et al. Synthesis and biological evaluation of 3,4,5-trimethoxy phenyl indol-3-ylmethane derivatives as potential antivascular agents. Bioorg Med Chem 2006; 14: 4410-26.
133. Hu L, Jiang J, Qu J, et al. Novel potent antimitotic heterocyclic ketones: Synthesis antiproliferative activity and structure-activity relationships. Bioorg Med Chem Lett 2007; 17: 3613-7.
134. Romagnoli R, Baraldi PG, Sarkar T, et al. Synthesis and biological evaluation of 1-Methyl-2-(3-4-5 trimethoxybenzoyl)-3-aminoindoles as a new class of antimitotic agents and tubulin inhibitors. J Med Chem 2008; 51: 1464-8.
135. Alvarez C, Alvarez R, Corchete P, et al. Diarylmethyloxime and hydrazone derivatives with 5-indolyl moieties as potent inhibitors of tubulin polymerization. Bioorg Med Chem 2008; 16: 5952-61.
136. Ty N, Dupeyre G, Chabot GG, et al. Synthesis and biological evaluation of new disubstituted analogs of 6-methoxy-3-(3'4'5'-Trimethoxybenzoyl)-1H-indole (BPR0L075) as potential antivascular agents. Bioorg Med Chem 2008; 16: 7494-503.
137. Wu YS, Coumar MS, Chang JY, et al. Synthesis and evaluation of 3-Aroylindoles as anticancer agents: metabolite approach. J Med Chem 2009; 52: 4941-5.
138. Arthuis M, Pontikis R, Chabot GG, Quentin L, Scherman D, Florent JC. Domino approach to 2-aroyltrimethoxyindoles as novel heterocyclic combretastatin A-4 analogs. Eur J Med Chem 2011; 46: 95-100.
139. Pinney KG, Bounds AD, Dingerman KM, et al. A new antitubulin agent containing the benzo[b]thiophene ring system. Bioorg Med Chem Lett 1999; 9: 1081-6.
140. Romagnoli R, Baraldi PG, Jung MK, et al. Synthesis and preliminary biological evaluation of new antitubulin agents containing different benzo heterocycles. Bioorg Med Chem Lett 2005; 15: 4048-52.
141. Romagnoli R, Baraldi PG, Carrion MD, et al. Substituted 2-(3'4'5'-trimethoxybenzoyl)-benzo[b]thiophene derivatives as potent tubulin polymerization inhibitors. Bioorg Med Chem 2010; 18: 5114-22.
142. Romagnoli R, Baraldi PG, Cara CL, Hamel E, Basso G, Viola G. Synthesis and biological evaluation of 2-(3'4'5'-trimethoxybenzoyl)-3-aryl/arylaminobenzo[b] thiophene derivatives as a novel class of antiproliferative agents. Eur J Med Chem 2010; 45: 5781-91.
143. Flynn BL, Gill GS, Grobelny DW, et al. Discovery of 7-Hydroxy-6-methoxy-2-methyl-3-(3',4',5'-trimethoxybenzoyl)benzo[b]furan (BNC105) a tubulin polymerization inhibitor with potent antiproliferative and tumor vascular disrupting properties. J Med Chem 2011; 54: 6014-27.
144. Kremmidiotis G, Leske AF, Lavranos TC, et al. BNC105: A novel tubulin polymerization inhibitor that selectively disrupts tumor vasculature and displays single-agent antitumor efficacy. Mol Cancer Ther 2010; 9: 1562-73.
145. Romagnoli R, Baraldi PG, Sarkar T, et al. Synthesis and biological evaluation of 2-(3'4'5'-trimethoxybenzoyl)-3-N, N-dimethylamino benzo[b]furan derivatives as inhibitors of tubulin polymerization. Bioorg Med Chem 2008; 16: 8419-26.
146. Cheng H, Zhang L, Liu Y, et al. Design synthesis and discovery of 5-hydroxyaurone derivatives as growth inhibitors against HUVEC and some cancer cell lines. Eur J Med Chem 2010; 45: 5950-7.
147. Bailly C, Bal C, Barbier P, et al. Synthesis and biological evaluation of 4-arylcoumarin analogs of combretastatins. J Med Chem 2003; 46: 5437-44.
148. Kemnitzer W, Kasibhatla S, Jiang S, et al. Discovery of 4-aryl-4Hchromenes as new series of apoptosis inducers using a cell-and caspase-based high-throughput screening assay. 1. Structureactivity relationships of the 4-aryl group. J Med Chem 2004; 47: 6299-310.
149. Gourdeau H, Leblond L, Hamelin B, et al. Antivascular and antitumor evaluation of 2-amino-4-(3-bromo-4,5-dimethoxy-phenyl)-3-cyano-4H-chromenes a novel series of anticancer agents. Mol Cancer Ther 2004; 3: 1375-83.
150. Kemnitzer W, Kasibhatla S, Jiang S, et al. Discovery of 4-aryl-4Hchromenes as new series of apoptosis inducers using a cell-and caspase-based high-throughput screening assay. 2. Structureactivity relationships of the 7-and 5-, 6-, 8-positions. Bioorg Med Chem Lett 2005; 15: 4745-51.
151. Kemnitzer W, Drewe J, Jiang S, et al. Discovery of 4-aryl-4Hchromenes as new series of apoptosis inducers using a cell-and caspase-based high throughput screening assay. 3. Structureactivity relationships of fused rings at the 7, 8-positions. J Med Chem 2007; 50: 2858-64.
152. Kemnitzer W, Kasibhatla S, Jiang S, et al. Discovery of 4-Aryl-4Hchromenes as a new series of apoptosis inducers using a cell-and caspase-based high throughput screening assay. 4. Structureactivity relationships of N-alkyl substituted pyrrole fused at the 7, 8-positions. J Med Chem 2008; 51: 417-23.
153. Ganina OG, Daras E, Bourgarel-Rey V, et al. Synthesis and biological evaluation of polymethoxyl-ated 4-heteroarylcoumarins as tubulin assembly inhibitor. Bioorg Med Chem 2008; 16: 8806-12.
154. Combes S, Barbier P, Douillard S, et al. Synthesis and biological evaluation of 4-arylcoumarin analogs of combretastatins Part 2. J Med Chem 2011; 54: 3153-62.
155. Hour MJ, Huang LJ, Kuo SC, et al. 6-Alkylamino-and 2,3-dihydro-3β-methoxy-2-phenyl-4-quinazolinones and related compounds: their synthesis cytotoxicity and inhibition of tubulin polymerization. J Med Chem 2000; 43: 4479-87.
156. Xia Y, Yang ZY, Hour MJ, et al. Antitumor agents. Part 204: synthesis and biological evaluation of substituted 2-aryl quinazolinones. Bioorg Med Chem 2001; 11: 1193-6.
157. Raffa D, Edler MC, Daidone G, et al. Synthesis cytotoxicity and inhibitory effects on tubulin polymerization of a new 3-heterocyclo substituted 2-styrylquinazolinones. Eur J Med Chem 2004; 39: 299-304.
158. Liu G, Hu D, Jin L, et al. Synthesis and bioactivities of 6,7,8-trimethoxy-Naryl-4-aminoquinazoline derivatives. Bioorg Med Chem 2007; 15: 6608-17.
159. Chinigo GM, Paige M, Grindrod S, Hamel E, Dakshanamurthy S, Chruszcz M. Minor W, Brown ML. Asymmetric synthesis of 2, 3-Dihydro-2-arylquinazolin-4-ones: Methodology and application to a potent fluorescent tubulin inhibitor with anticancer activity. J Med Chem 2008; 51: 4620-31.
160. Nien CY, Chen YC, Kuo CC, et al. 5-Amino-2-aroylquinolines as highly potent tubulin polymerization inhibitors. J Med Chem 2010; 53; 2309-13.
161. Kong Y, Grembecka J, Edler MC, Hamel E, Mooberry SL, Sabat M, Rieger J, Brown ML. Structure based discovery of a boronic acid biostere of combretastatin A-4. Chem Biol 2005; 12: 1007-14.
162. Ducki S, Mackenzie G, Greedy B, et al. Combretastatin-like chalcones as inhibitors of microtubule polymerization. Part 2: Structure-based discovery of alpha-aryl chalcones. Bioorg Med Chem 2009; 17: 7711-22.